Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an established treatment for selected peritoneal surface malignancies. However, awareness, training exposure, and attitudes toward CRS-HIPEC vary among oncologic disciplines. This nation sample study aimed to assess and compare the knowledge, awareness, and perceptions of surgical and medical oncologists in Türkiye regarding CRS-HIPEC indications, benefits, and implementation. A cross-sectional, web-based survey was conducted between July and December 2025 among certified surgical and medical oncologists. A 19-item questionnaire evaluated demographics, CRS-HIPEC training exposure, institutional practices, and attitudes using a five-point Likert scale. A total of 98 oncologists participated (50 surgical, 48 medical), corresponding to an overall response rate of 36.3%. HIPEC-related training was significantly more common among surgical oncologists (39/50, 78% vs 13/48, 27%; p < 0.001), as were higher self-rated knowledge levels (p < 0.001) and awareness of CRS-HIPEC indications (40/50, 80% vs 28/48, 58%; p = 0.035). Agreement with the statement that CRS-HIPEC improves survival in appropriately selected patients was also stronger among surgical oncologists (44/50, 88% vs 35/48, 73%; p = 0.006). Among medical oncologists, those participating in multidisciplinary tumor boards were more likely to agree with the survival benefit (p = 0.032). Overall, 92% of participants supported the need for a national CRS-HIPEC guideline or standardized protocol. Surgical oncologists report greater training exposure and stronger belief in the benefit of CRS-HIPEC; however, multidisciplinary collaboration enhances understanding and acceptance among medical oncologists. Unified national guidelines and structured training programs may help align perspectives and optimize multidisciplinary practice.
Güler et al. (Tue,) studied this question.